Table 1

Summary of baseline characteristics for TNFi-naïve PsA patients with PA-PRS. Data presented are n (%) or mean (SD)

PlaceboUstekinumabAll
45 mg90 mgCombinedPatients
Allpatients(N)846673139223
Male42 (50.0)37 (56.1)48 (65.8)85 (61.2)127 (57.0)
Age (years)47.01 (12.87)45.56 (11.62)45.67 (11.66)45.62 (11.60)46.14 (12.09)
Body-mass index (kg/m2)28.96 (6.35)28.06 (5.16)28.69 (5.58)28.39 (5.38)28.60 (5.76)
Duration of disease (years)
 PsA7.11 (8.80)6.28 (6.77)6.48 (6.36)6.39 (6.54)6.66 (7.46)
 Psoriasis15.95 (12.82)14.58 (10.97)16.64 (12.34)15.66 (11.71)15.77 (12.12)
Patient with ≥3% BSA psoriasis63 (75.0)57 (86.4)59 (80.8)116 (83.5)179 (80.3)
 PASI score (0–72)14.46 (12.53)15.11 (13.58)13.86 (10.22)14.48 (11.95)14.47 (12.12)
 DLQI score (0–30)13.13 (8.01)12.54 (7.13)11.75 (7.08)12.14 (7.09)12.49 (7.42)
Swollen joint count (0–66)15.79 (11.02)12.76 (7.93)12.38 (8.99)12.56 (8.48)13.78 (9.62)
Tender joint count (0–68)25.04 (14.85)24.33 (15.50)21.16 (12.92)22.67 (14.24)23.56 (14.48)
Spondylitis-related activity (0–10)
 BASDAI total neck/back/hip pain6.14 (2.74)6.62 (2.31)6.84 (2.15)6.74 (2.22)6.51 (2.44)
 mBASDAI (excl. peripheral)6.27 (1.84)6.52 (1.71)6.56 (1.63)6.54 (1.66)6.44 (1.73)
BASDAI6.37 (1.74)6.57 (1.62)6.60 (1.60)6.59 (1.61)6.51 (1.66)
 ASDAS-CRP3.68 (0.88)3.86 (0.91)3.90 (0.87)3.88 (0.89)3.81 (0.89)
CRP (mg/L)18.57 (25.72)20.30 (23.19)20.63 (20.74)20.47 (21.85)19.76 (23.35)
HAQ-DI score (0–3)1.36 (0.63)1.33 (0.60)1.22 (0.66)1.27 (0.63)1.30 (0.63)
DAS28-CRP5.25 (1.11)5.27 (0.98)5.11 (0.90)5.18 (0.94)5.21 (1.01)
Dactylitis in ≥1 digit43 (51.2)38 (57.6)30 (41.1)68 (48.9)111 (49.8)
 Dactylitis score (0–60)9.88 (12.21)8.05 (11.00)6.70 (5.99)7.46 (9.10)8.40 (10.43)
Enthesitis66 (78.6)56 (84.8)57 (78.1)113 (81.3)179 (80.3)
 Enthesitis score (0–15)5.23 (4.18)5.04 (2.99)6.54 (4.15)5.80 (3.68)5.59 (3.87)
Methotrexate33 (39.3)33 (50.0)41 (56.2)74 (53.2)107 (48.0)
 Mean dose (SD) (mg/week)15.83 (4.87)14.09 (4.18)14.82 (3.97)14.49 (4.05)14.91 (4.34)
Corticosteroids16 (19.0)17 (25.8)14 (19.2)31 (22.3)47 (21.1)
 Mean dose (SD) (mg/day)6.84 (2.23)7.71 (2.78)6.54 (2.76)7.18 (2.79)7.06 (2.59)
HLA-B27+patients* (N)1313142740/158 (25.3)
Age
 <45 years7 (53.8)9 (69.2)8 (57.1)17 (63.0)24 (60.0)
 ≥45 years6 (46.2)4 (30.8)6 (42.9)10 (37.0)16 (40.0)
Spondylitis-related activity (0–10)
 BASDAI total neck/back/hip pain5.54 (2.32)7.55 (2.29)7.40 (1.85)7.47 (2.03)6.88 (2.28)
 mBASDAI (excl. peripheral)5.99 (1.33)7.16 (1.78)7.02 (1.55)7.09 (1.63)6.75 (1.61)
 BASDAI6.18 (1.31)7.12 (1.66)6.97 (1.59)7.04 (1.59)6.78 (1.55)
 ASDAS-CRP3.76 (0.82)4.55 (0.95)4.09 (0.79)4.31 (0.88)4.14 (0.89)
 <45 years3.85 (0.68)4.85 (0.67)3.97 (0.84)4.44 (0.86)4.27 (0.84)
 ≥45 years3.64 (1.05)3.87 (1.23)4.25 (0.76)4.10 (0.93)3.95 (0.96)
CRP (mg/L)26.30 (46.20)42.46 (38.05)20.60 (22.22)31.12 (32.23)29.56 (36.80)
HLA-B27patients* (N)47323971118/158 (74.7)
Age
 <45 years19 (40.4)11 (34.4)22 (56.4)33 (46.5)52 (44.1)
 ≥45 years28 (59.6)21 (65.6)17 (43.6)38 (53.5)66 (55.9)
Spondylitis-related activity (0–10)
 BASDAI total neck/back/hip pain6.20 (2.76)6.53 (2.28)6.76 (2.03)6.66 (2.13)6.48 (2.40)
 mBASDAI (excl. peripheral)6.29 (1.87)6.42 (1.93)6.63 (1.66)6.54 (1.77)6.44 (1.81)
 BASDAI6.41 (1.72)6.45 (1.83)6.67 (1.63)6.57 (1.71)6.51 (1.71)
 ASDAS-CRP3.67 (0.83)3.64 (0.87)3.88 (0.84)3.78 (0.86)3.74 (0.84)
 <45 years3.68 (0.98)3.95 (1.10)3.81 (0.69)3.86 (0.82)3.79 (0.88)
 ≥45 years3.67 (0.73)3.49 (0.71)3.97 (1.02)3.71 (0.89)3.69 (0.82)
CRP (mg/L)17.24 (20.63)12.60 (9.77)19.61 (18.74)16.45 (15.66)16.76 (17.73)
  • *Does not include three patients with testing for whom the HLA-B27 genotype could not be determined.

  • ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score incorporating C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BSA, body surface area; CRP, C-reactive protein; DAS28-CRP, disease activity score 28-CRP; DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire Disability Index; HLA-B27, human-leucocyte-antigen B27 allele; mBASDAI, modified Bath Ankylosing Spondylitis Disease Activity Index; PA-PRS, peripheral arthritis and physician-reported spondylitis; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; TNFi, tumour necrosis factor-inhibitor.